... CONCLUSIONS AND RECOMMENDATIONS Current therapy of chronichepatitisB has limited long- term efficacy. Thus, careful consideration of severity of liver disease, likelihood of response, and potential ...
... of chronichepatitisB virus infection, immune-tolerant phase is characterized by high viral replication, the presence of HBV e antigen (HBeAg), and normal or minimally elevated serum alanine ...
... In most cases, infection-associated aPLs appear tempora- rily and disappear within 2 or 3 months [24, 25], and except in rare cases, they are unrelated to thrombotic complications. Contrary to previous reports, in the ...
... for chronichepatitisB virus (HBV) infection is to eliminate or suppress HBV with the aim of preventing the devastating complications of cirrhosis, hepatic failure, and hepatocellular ...for ...
... Yuen MF , Hui CK , Cheng CC , Wu CH , Lai YF , Lai CL Long-term fol1ow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection 매 e effect on hepatitis B e [r] ...
... with chronichepatitisB infection is to prevent progression of the disease to cirrhosis and hepatocellular ...of chronichepatitisB (CHB) medications in South Korea between ...
... The endpoint of treatment for HBeAg-negative chronichepatitisB is not established. HBeAg loss or se- roconversion cannot be used to define response and treat- ment usually focuses on suppression of ...
... Various rescue therapies have been used for CLV-resistant This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ...
... INTRODUCTION ChronichepatitisB virus (HBV) infection is the main cause of cirrhosis, hepatic failure, and hepatocellular carcinoma (HCC) globally [1] ...Of chronic HBV carriers, ...
... with chronichepatitisB infection and lab findings were within normal range, the CT scan showed hepatosplenomegaly and multiple lymph node ...vealed chronic granulomatous inflammation showing ...
... Eum, S. Effect of the structured education for knowledge of hepatitis B type and self- care behavior in chronic hepatitis B patients. Chronic disease self-management and adherence to [r] ...
... We investigated the pattern of mutations in and outside of YMDD motif of HBV reverse transcriptase gene during lamivudine therapy in patients with chronic hepatitis B infection.. Methods[r] ...
... Tenofovir may be the best option, but it is still not available in many countries. Where tenofovir is not available, adefovir plus entecavir can be considered an alternative treatment option in patients with favorable ...
... 만성 B형간염의 자연경과는 1) immune tolerance phase, 2) immune clearance phase, 3) immune control/inactive phase, 4) reactivation/HBeAg negative hepatitis와 같이 크게 4개의 phase로 나눌 수 있다. 모든 환자가 4개의 phase 를 순차적으로 경험하는 것은 아니며 phase 간 이동이 ...
... hronic hepatitisB infection is the most common cause of chronic liver diseases in Korea and can induce chronichepatitis, liver cirrhosis, and hepatocellular ...
... 1) 직접 작용 항바이러스제 (1) HBV entry inhibitors 최근 HBV가 숙주세포 내로의 진입에 중요한 역할을 하는 NTCP 수용체가 발견되면서 진입 억제제(entry inhibitor)의 개발이 시작되었다. 가장 대표적인 myrcludex B는 NTCP 수 용체에 HBV와 경쟁적으로 결합하여, HBV의 결합과 침입을 막는 합성 지방펩티드(lipopeptide)이다. 간세포 ...